	US 11,718,686 B2
	Anti-transglutaminase 2 antibodies
Tim Johnson, Sheffield (GB); Phil Watson, Sheffield (GB); David Matthews, Sheffield (GB); and Alex Brown, London (GB)
Assigned to LIFEARC, London (GB)
Filed by LIFEARC, London (GB)
Filed on Dec. 14, 2020, as Appl. No. 17/121,541.
Application 17/121,541 is a continuation of application No. 15/987,611, filed on May 23, 2018, granted, now 10,961,319.
Application 15/987,611 is a continuation of application No. 14/402,675, granted, now 10,005,846, previously published as PCT/GB2013/051373, filed on May 24, 2013.
Claims priority of application No. 1209096 (GB), filed on May 24, 2012.
Prior Publication US 2021/0101999 A1, Apr. 8, 2021
Int. Cl. C07K 16/00 (2006.01); A61K 39/00 (2006.01); C07K 16/40 (2006.01); A61K 51/10 (2006.01)

CPC C07K 16/40 (2013.01) [A61K 51/1075 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/76 (2013.01)]

12 Claims

1. An antibody or an antigen-binding fragment thereof that binds human transglutaminase type 2 (TG2), wherein the antibody or antigen-binding fragment thereof comprises the amino acid sequences set forth in SEQ ID NO: 7 (LCDR1; KASQDINSYLT), SEQ ID NO: 13 (LCDR2; LTNRLMD), SEQ ID NO: 14 (LCDR3; LQYVDFPYT), SEQ ID NO: 10 (HCDR1; SSAMS), SEQ ID NO: 15 (HCDR2; TISSGGRSTYYPDSVKG) and SEQ ID NO: 16 (HCDR3; LISPY).